Navigation Links
Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
Date:10/21/2008

ce Letters by Eurand and Cephalon. The companies will work together to determine the most appropriate course of action.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets (C-IV), TREANDA(R) (bendamustine hydrochloride), FENTORA(R) (fentanyl buccal tablet) (C-II), TRISENOX(R) (arsenic trioxide) injection, AMRIX, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets (C-IV) and ACTIQ(R) (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized rel
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... available in German . ... the naked eye, you can see which branch a bird ... of branches through the telephoto lens for high-magnification images requires ... are looking to study proteins, the active biomolecules of cells. ... for Molecular Systems Biology, and her colleagues have now come ...
(Date:5/17/2013)... PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New ... insect pressures , Syngenta unveiled ... celebration today at the company’s RTP Innovation Center. The ... allows company researchers to simulate any agricultural climate and ...
(Date:5/17/2013)... May 17, 2013  Yongye International, Inc. (NASDAQ: ... developer, manufacturer, and distributor of crop nutrient products in ... today announced that, on May 16, 2013, the special ... (the "Board of Directors") was provided a letter (the ... Kong ) Limited ("Abax") to Full Alliance International ...
(Date:5/17/2013)... FL (PRWEB) May 17, 2013 Men’s skin ... La-roche Posay ) and has been known to ... Although some men may be far from puberty, other acne ... clogging pores, causing breakouts, and threatening skin with unsightly acne ... advice from Men’s Health on how to reduce ...
Breaking Biology Technology:Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... opportunities noted that the FDA sees radio frequency identification ... integrity of the U.S. drug supply. RFID allows pharmaceutical ... chain of distribution from manufacturer to pharmacy. , ... an initiative to improve identification ...
... College in Eau Claire are offering up to eight ... firms or organizations with an economic interest in nanotechnology ... comprise each of five teams with project completion by ... the purchase of an electron microscope are the best ...
... Fiserv, Inc. announced strong earnings for the third ... for the third quarter of 2005 was $0.58 per share, ... 2004. Processing and services revenues were $925.3 million, an increase ... "We are also very excited about our recent acquisitions, including ...
Cached Biology Technology:RFID medical devices - Opportunities and challenges 2RFID medical devices - Opportunities and challenges 3RFID medical devices - Opportunities and challenges 4
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
(Date:5/17/2013)... noise of the South, but the night belongs to the ... heavy from the humidity and the sounds of wildlife. ... frogs, toads and salamanders, is the center of amphibian biodiversity ... the auditorium for their symphonic choruses, the scientists of the ... have front-row seats. , Amphibians, which rely on ...
(Date:5/17/2013)... 2013, Shenzhen, China---- Why Tibetan antelope can live ... In a collaborative research published in Nature ... other institutes provide evidence that some genetic factors ... harsh highland environments. The data in this work ... mechanisms and the biology of other ruminant species. ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... all go a little gooey, but it,s not turning mums, ... Australian National University. The study conducted by the ... that despite fears mothers may have that pregnancy affects their ... true. The findings have been released as part of Mental ...
... CT Contrary to conventional wisdom, tropical plant and animal ... may be threatened by global warming, according to an article ... in this week,s (Oct. 10) issue of Science ... the geographical ranges of well-studied bird, butterfly, and plant species ...
... of patients with compromised immune systems has grown ... unique set of healthcare solutions that take into ... immune suppression to the individual patient,s nutritional status. ... of the Immunocompromised Host,examines a wide range of ...
Cached Biology News:Pregnancy not turning minds to mush: Study 2Tropical rainforest and mountain species may be threatened by global warming 2Text focuses on diagnosing infections in immunocompromised patients 2